SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Imara, Inc. (Nasdaq – IMRA)

BALA CYNWYD – October 13, 2022 /Globe Newswire/ – Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Imara, Inc. (“Imara” or the “Company”) (Nasdaq – IMRA) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the Company’s agreement to merge with Enliven Therapeutics, Inc. (“Enliven”). Under the terms of the merger agreement, Imara will issue to pre-merger Enliven stockholders shares of Imara common stock as merger consideration in exchange for the cancellation of shares of capital stock of Enliven and Enliven will become a wholly-owned subsidiary of Imara. Pre-merger Imara stockholders are expected to own approximately 16% of the combined company and pre-merger Enliven stockholders are expected to own approximately 84% of the combined company.

The investigation concerns whether the Imara Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution to Imara shareholders in the combined company.

If you own shares of Imara stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, Two Bala Plaza, Suite 805, Bala Cynwyd, PA 19004, or call toll free 855-576-4847.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.